/PBYI
PBYI Stock - Puma Biotechnology, Inc.
Healthcare|BiotechnologyNASDAQ
$5.63+0.18%
+$0.01 (+0.18%) • Dec 19
73
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.95
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.73
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $6.19
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PBYI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.57 – $5.69
TARGET (TP)$6.47
STOP LOSS$5.18
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.16
52W High$6.12
52W Low$2.58
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $230.47M | $235.64M | $228.03M | $253.16M | $225.11M |
| Gross Profit | $166.06M | $172.96M | $172.94M | $189.45M | $185.74M |
| Gross Margin | 72.1% | 73.4% | 75.8% | 74.8% | 82.5% |
| Operating Income | $30.97M | $32.64M | $23.72M | $1.29M | $-30,402,000 |
| Net Income | $30.28M | $21.59M | $2,000 | $-29,126,000 | $-59,995,000 |
| Net Margin | 13.1% | 9.2% | 0.0% | -11.5% | -26.7% |
| EPS | $0.62 | $0.46 | $0.02 | $-0.72 | $-1.52 |
Company Overview
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PBYIBeat Rate
83%
Last 18 quarters
Avg Surprise
+837.3%
EPS vs Estimate
Beats / Misses
15/3
Last 12 quarters
Latest EPS
$0.21
Q4 2025
EPS Surprise History
Q1 24
-13.3%
$0.26vs$0.30
Q2 24
+68.8%
$-0.05vs$-0.16
Q3 24
+50.0%
$-0.05vs$-0.10
Q4 24
+17.1%
$0.41vs$0.35
Q1 25
+330.0%
$0.43vs$0.10
Q2 25
+400.0%
$0.10vs$0.02
Q3 25
+36.4%
$0.15vs$0.11
Q4 25
+133.3%
$0.21vs$0.09
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $0.24 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.09 | $0.21 | +133.3% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $0.11 | $0.15 | +36.4% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $0.02 | $0.10 | +400.0% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $0.10 | $0.43 | +330.0% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $0.35 | $0.41 | +17.1% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-0.10 | $-0.05 | +50.0% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.16 | $-0.05 | +68.8% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $0.30 | $0.26 | -13.3% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $0.08 | $0.12 | +50.0% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $0.07 | $0.10 | +42.9% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $0.04 | $0.09 | +142.8% | ✓ BEAT |
Q1 2023 | Mar 2, 2023 | $0.06 | $-0.12 | -300.0% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.11 | $-0.01 | +90.9% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $0.00 | $0.21 | +14089.2% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.13 | $-0.08 | +38.5% | ✓ BEAT |
Q1 2022 | Mar 3, 2022 | $-0.09 | $0.10 | +211.1% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-0.23 | $-1.09 | -373.9% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.31 | $-0.13 | +58.1% | ✓ BEAT |
Latest News
Puma Biotechnology shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q3 sales guidance above estimates. Also, the company raised its FY25 sales guidance above estimates.
📈 PositiveBenzinga•Nov 7, 2025, 04:15 PM
Puma Biotechnology Raises FY2025 Sales Guidance from $212.000M-$222.000M to $220.000M-$223.000M vs $216.500M Est
📈 PositiveBenzinga•Nov 6, 2025, 09:07 PM
Puma Biotechnology Sees Q4 Sales $67.000M-$70.000M vs $66.600M Est
📈 PositiveBenzinga•Nov 6, 2025, 09:06 PM
Puma Biotechnology Q3 Adj. EPS $0.21 Beats $0.04 Estimate, Sales $54.500M Beat $51.000M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 09:06 PM
Frequently Asked Questions about PBYI
What is PBYI's current stock price?
Puma Biotechnology, Inc. (PBYI) is currently trading at $5.63 per share. The stock has moved +0.18% today.
What is the analyst price target for PBYI?
No analyst price targets are currently available for this stock.
What sector is Puma Biotechnology, Inc. in?
Puma Biotechnology, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PBYI's market cap?
Puma Biotechnology, Inc. has a market capitalization of $0.28 billion, making it a small-cap company.
Does PBYI pay dividends?
No, Puma Biotechnology, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABEO
Abeona Therapeutics Inc.
$5.11
Mkt Cap: $0.3B
ALLO
Allogene Therapeutics, Inc.
$1.42
Mkt Cap: $0.3B
ARCT
Arcturus Therapeutics Holdings Inc.
$6.53
Mkt Cap: $0.2B
AVIR
Atea Pharmaceuticals, Inc.
$3.14
Mkt Cap: $0.2B
ELDN
Eledon Pharmaceuticals, Inc.
$1.64
Mkt Cap: $0.1B
HUMA
Humacyte, Inc.
$1.11
Mkt Cap: $0.2B
SGMT
Sagimet Biosciences Inc.
$6.28
Mkt Cap: $0.2B
TRDA
Entrada Therapeutics, Inc.
$10.98
Mkt Cap: $0.4B
VYGR
Voyager Therapeutics, Inc.
$4.00
Mkt Cap: $0.2B
Explore stocks similar to PBYI for comparison